These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9144852)

  • 21. Societal costs of rheumatoid arthritis in Hong Kong: a prevalence-based cost-of-illness study.
    Zhu TY; Tam LS; Li EK
    Rheumatology (Oxford); 2011 Jul; 50(7):1293-301. PubMed ID: 21330341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient self-efficacy and health locus of control: relationships with health status and arthritis-related expenditure.
    Cross MJ; March LM; Lapsley HM; Byrne E; Brooks PM
    Rheumatology (Oxford); 2006 Jan; 45(1):92-6. PubMed ID: 16287930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An economic approach to health care.
    Homik JE; Suarez-Almazor M
    Best Pract Res Clin Rheumatol; 2004 Apr; 18(2):203-18. PubMed ID: 15121040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The costs of rheumatoid arthritis: an international long-term view.
    Pugner KM; Scott DI; Holmes JW; Hieke K
    Semin Arthritis Rheum; 2000 Apr; 29(5):305-20. PubMed ID: 10805355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis.
    Singh G; Miller JD; Huse DM; Pettitt D; D'Agostino RB; Russell MW
    J Rheumatol; 2003 Apr; 30(4):714-9. PubMed ID: 12672188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug utilization review of celecoxib in Ontario.
    LeLorier J; Fitzsimon C; Keresteci M; Stewart D; Lavoie F
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii11-6. PubMed ID: 14585913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic burden of rheumatoid arthritis: a systematic review.
    Cooper NJ
    Rheumatology (Oxford); 2000 Jan; 39(1):28-33. PubMed ID: 10662870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness and cost utility analysis of multidisciplinary care in patients with rheumatoid arthritis: a randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care.
    van den Hout WB; Tijhuis GJ; Hazes JM; Breedveld FC; Vliet Vlieland TP
    Ann Rheum Dis; 2003 Apr; 62(4):308-15. PubMed ID: 12634227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balneotherapy for rheumatoid arthritis and osteoarthritis.
    Verhagen AP; de Vet HC; de Bie RA; Kessels AG; Boers M; Knipschild PG
    Cochrane Database Syst Rev; 2000; (2):CD000518. PubMed ID: 10796385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of total hip and knee joint replacement in patients with rheumatoid arthritis and osteoarthritis: a nationwide, population-based study.
    Liao CY; Chan HT; Chao E; Yang CM; Lu TC
    Singapore Med J; 2015 Jan; 56(1):58-64. PubMed ID: 25640101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
    Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies.
    Puig-Junoy J; Ruiz Zamora A
    Semin Arthritis Rheum; 2015 Apr; 44(5):531-541. PubMed ID: 25511476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.
    Xie F; Kovic B; Jin X; He X; Wang M; Silvestre C
    Pharmacoeconomics; 2016 Nov; 34(11):1087-1100. PubMed ID: 27339668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?
    Davies LM; Fargher EA; Tricker K; Dawes P; Scott DL; Symmons D
    Ann Rheum Dis; 2007 May; 66(5):658-63. PubMed ID: 17124249
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The need for standardization: a literature review of indirect costs of rheumatoid arthritis and osteoarthritis.
    Xie F
    Arthritis Rheum; 2008 Jul; 59(7):1027-33. PubMed ID: 18576305
    [No Abstract]   [Full Text] [Related]  

  • 37. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility of willingness-to-pay measurement in chronic arthritis.
    Thompson MS; Read JL; Liang M
    Med Decis Making; 1984; 4(2):195-215. PubMed ID: 6433140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Schoels M; Wong J; Scott DL; Zink A; Richards P; Landewé R; Smolen JS; Aletaha D
    Ann Rheum Dis; 2010 Jun; 69(6):995-1003. PubMed ID: 20447950
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).
    Wynne HA; Campbell M
    Pharmacoeconomics; 1993 Feb; 3(2):107-23. PubMed ID: 10146960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.